Özlem Türeci

Özlem Türeci is a Turkish-German physician and immunologist whose decades-long pursuit of teaching the immune system to fight cancer helped lay the foundation for one of the most consequential medical achievements of our age. As co-founder and chief medical officer of the German biotechnology company BioNTech, she played a central role, alongside her husband and scientific partner Uğur Şahin, in developing the messenger RNA (mRNA) technology that produced one of the first authorized COVID-19 vaccines. But long before the pandemic made that work famous, her life had been devoted to a quieter and more personal mission: helping patients whom medicine had too often been forced to abandon.

She was born in 1967 in Lastrup, a small town in Lower Saxony in northern Germany. Her father was a physician who had immigrated from Turkey and worked as a surgeon at a Catholic hospital in the region. Türeci has spoken of growing up close to medicine, of the hospital being almost an extension of the family’s world, and of seeing in her father a model of the doctor as someone wholly devoted to the care of others. That early immersion shaped a sense that medicine was not merely a profession but a vocation. She has recalled that as a child she even briefly considered becoming a nun, drawn to the idea of a life given over entirely to service—an impulse that would later find its outlet in science and in the care of the sick.

She studied medicine and trained as a physician, specializing in the area where immunology and cancer meet. Her clinical experience left her with a lasting awareness of the limits of the treatments then available and of the suffering of patients with cancers that did not respond to them. This was the wound that her career would seek to heal. She became convinced that the most promising path forward lay in immunotherapy—in mobilizing the patient’s own immune system, with its extraordinary capacity to recognize what is foreign and dangerous, to seek out and destroy tumor cells.

It was in this world of cancer immunology that she met Uğur Şahin. They discovered in each other not only personal companionship but a shared scientific vision pursued with rare intensity. The two became partners in every sense, and their collaboration would prove one of the most fruitful in modern medicine. They shared the conviction that scientific discoveries belonged not only in journals but at the bedside, and that bridging the gap between the laboratory and the patient would require them to build the institutions—companies as well as research groups—capable of carrying ideas all the way to approved therapies.

Türeci pursued an academic path, conducting research and teaching in the field of tumor immunology, and she and Şahin together identified molecular targets on cancer cells that might be exploited therapeutically. In 2001 they co-founded their first company, Ganymed Pharmaceuticals, which developed antibody-based cancer treatments and was eventually acquired. The experience demonstrated that the path they had chosen—translating immunological insight into real medicines—was viable, and it gave them the means and the confidence to pursue a far more ambitious vision.

That vision took shape in 2008 with the founding of BioNTech in Mainz, where Türeci served as chief medical officer. The company committed itself to the largely unproven promise of messenger RNA as a therapeutic platform. The underlying idea was elegant: deliver into the body synthetic mRNA carrying the instructions to make a chosen protein, and thereby direct the immune system’s attention to a target of one’s choosing. Türeci was especially focused on the dream of individualized cancer vaccines—treatments designed against the unique constellation of mutations in a particular patient’s tumor, so that the immune system could be trained to attack that patient’s cancer specifically. It was a vision of medicine as precise and personal as the disease it sought to defeat.

For more than a decade this was demanding, often invisible work, requiring the solution of formidable technical problems in the design, stabilization, and delivery of mRNA. BioNTech grew into a research-driven enterprise sustained by conviction rather than by approved products. As chief medical officer, Türeci was deeply involved in steering the company’s clinical strategy and in the rigorous testing required to move candidate therapies toward patients. It was painstaking work undertaken in the belief that the platform, once mature, could transform the treatment of cancer and other diseases.

When the COVID-19 pandemic struck in 2020, BioNTech’s years of patient preparation suddenly met a global emergency. The same mRNA technology developed with cancer in mind could be redirected against the new coronavirus with remarkable speed. Türeci helped lead the medical and clinical dimensions of the effort the company called “Project Lightspeed,” undertaken in partnership with Pfizer. Within months, the team designed, tested, and shepherded through clinical trials a vaccine that proved highly effective. In late 2020 it became among the first COVID-19 vaccines authorized for use, and in the years that followed hundreds of millions of doses were administered worldwide, helping to save countless lives.

Amid the global attention, Türeci became one of the most prominent women in science and a symbol of what immigrant families and dedicated researchers could contribute to their society and the world. Yet she, like her husband, remained known for modesty and for keeping the focus on the patients and the science rather than on fame. She has spoken thoughtfully in interviews about the responsibility that comes with scientific power, about the importance of trust between scientists and the public, and about the long road of research that lies behind any sudden breakthrough.

Throughout, she has insisted that the COVID-19 vaccine, however momentous, was in a sense a proof of concept for the broader promise of mRNA—and that the original goal remains the conquest of cancer. Under her medical leadership, BioNTech has continued to advance individualized cancer vaccines and other immunotherapies through clinical trials. The future she envisions is one in which a patient’s tumor can be analyzed, a tailored vaccine rapidly produced, and the immune system armed to eliminate the disease—a future that the pandemic, for all its devastation, may have helped bring nearer.

Türeci has received numerous honors, often jointly with Şahin, in recognition of her contributions to medicine and public health, and she has been celebrated as one of Germany’s most distinguished scientists. But her deeper legacy lies in the union of compassion and rigor that has marked her work. She entered medicine drawn by the desire to serve, carried that desire into the laboratory, and refused to accept the limits that conventional treatment imposed on patients. Her perseverance through years of uncertainty, in service of an idea that many doubted, ultimately bore fruit at a moment of worldwide need.

Her story carries a quiet and powerful lesson, particularly for young women and for all who dream of using knowledge in the service of others. She shows that compassion and scientific rigor are not opposites but partners, that a life devoted to a worthy purpose can endure long stretches of doubt and difficulty, and that patient, sincere effort may one day become a mercy to people one will never meet. In her devotion, her humility, and her steadfast pursuit of a healing purpose, Özlem Türeci offers an example of how the gifts of the mind, joined to a caring heart, can serve the whole of humanity.